Turn Therapeutics 于 2025 年 10 月 22 日推出了一系列网络研讨会，以更新其皮肤病学、伤口护理和疫苗计划，此前该公司于 10 月 8 日公开首次亮相并获得了 $75M 的融资。 Turn Therapeutics launched a webinar series on Oct. 22, 2025, to update on its dermatology, wound care, and vaccine programs, following its Oct. 8 public debut and $75M financing.

转基因治疗(Nasdaq: TTRX)于2025年10月22日推出连环网络研讨会系列, 分享皮肤病学、伤口护理和传染病方案的最新情况, Turn Therapeutics (Nasdaq: TTRX) launched a recurring webinar series on October 22, 2025, to share updates on its dermatology, wound care, and infectious disease programs, including late-stage clinical trials for eczema and onychomycosis, and thermostable vaccine delivery research. 该公司于2025年10月8日通过直接上市上市,获得了三项FDA许可,并正在以7500万美元融资承诺的支持推进开发. The company, which went public via a direct listing on October 8, 2025, received three FDA clearances and is advancing development with support from a $75 million financing commitment. CEO Bradley Burnam的创始人博客将提供有关公司进展和研究的见解。 A Founder Blog by CEO Bradley Burnam will provide insights on company progress and research. 网上研讨会录音和材料将张贴在网上。 Webinar recordings and materials will be posted online. 该公司报告说,从2023年1月至2025年6月,业务损失为586万美元,预计将在里程碑付款和许可证交易的支持下,继续运营一至两年。 The company reported operating losses of $5.86 million from January 2023 to June 2025 and expects to remain operational for one to two years, supported by milestone payments and licensing deals.